Progress has been shown in the death rates from prostate cancer and the other three leading cancers-lung, breast, and colorectal. Deaths from prostate cancer have fallen 4.0% during the 5-year period from 1996 to 2000. Bladder cancer decreased by 0.4% over the same period.
With the help of state legislators, physicians in Philadelphia have something to celebrate.
A new prognostic model could decrease the number of unneeded prostate biopsies by 24% without sacrificing cancer detection, according to a study to be published in the October 1, 2003, issue of Cancer.
Patients with locally advanced bladder cancer have more than a fighting chance for survival with neoadjuvant chemotherapy, which has been found to provide a longer life in patients compared with the standard treatment of surgery alone, according to an 11-year study published in the New England Journal of Medicine (2003; 349:859-66).
Nearly 700,000 physicians nationwide are the beneficiaries of a settlement requiring CIGNA Healthcare to institute new business practices.
An oral bisphosphonate may slow the development of symptomatic bone metastases and reduce the risk of death from this disease, new data show.
References
Increasing knowledge of the ways in which we differ from each other genetically has the potential to change the way medicine is practiced in the not too distant future.88 One of the most common forms of human genetic diversity is the single nucleotide polymorphism (SNP), a single base-pair position in genomic DNA at which different sequence alternatives (alleles) exist in normal individuals.
In the developed world, environmental factors-particularly diet-seem to play a prominent role in the development of prostate cancer.27 Research into the molecular pathogenesis of prostate cancer may help us assess why prostate cells are particularly vulnerable to such environmental effects and to determine what somatic genome mutations are involved in the transformation of normal epithelium into intraepithelial neoplasia (PIN) and ultimately to invasive carcinoma (Figure 5).
Chemoprevention is the use of natural or synthetic agents to avert the induction of, or to inhibit, delay, or suppress the progression of cancers or other diseases. Carcinogenesis is a process that occurs over a period of months to years and is under the influence of a range of genetic and environmental factors.
Prostate cancer is the most common nonskin malignancy among men in Europe, North America, and Australia and, after lung cancer, represents the second leading cause of cancer-related death in men in these regions.4 Data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, which covers approximately 26% of the US population, show the rising incidence of cancer of the prostate (Figure 1).
In the field of prostate cancer, one of the key goals of researchers and physicians is to reduce the morbidity and mortality associated with the condition. Strategies to help achieve this goal include screening, surgery, therapy (pharmacological, chemotherapy, and radiotherapy), and prevention.
Consolidating research institutions would improve collaboration and datasharing
Urology has always been a fascinating and somewhat hybrid specialty inthe field of medicine. First and foremost, it has been a surgical specialty,requiring many years of intense surgical training to master. Many of ushave been drawn to urology because of the wide assortment of surgical proceduresand the ability to put to use the highest technological advancements inthe course of our work.
Take advantage of a high-capacity Internet connection when setting upmeetings
Physician must be immediately available, and the service must be performedby an employee
The out-of-pocket expenditures needed to buy the equipment used in every practice have always been reduced or helped by our tax laws. Today, thanks to the new Jobs and Growth Tax Relief Reconciliation Act of 2003, the needed equipment may be more affordable than ever.
Keep these suggestions in mind to avoid obstacles and hostility duringyour transfer
Chicago-Real-world clinical practice data provide further evidencethat treatment with a 5-alpha-reductase inhibitor significantly reducesthe risks for progression to acute urinary retention (AUR), catheterization,or surgery in men with BPH, according to a retrospective analysis from theUnited Kingdom.
New York-A combination of hormonal therapy, brachytherapy, andexternal beam radiation has demonstrated excellent local control in high-riskprostate cancer patients.
Chicago-Adjuvant androgen ablation following radiation therapysignificantly reduces the risk of local and distant failure and significantlyimproves overall survival in patients with unfavorable-prognosis prostatecancer, according to 10-year results from a large cooperative group trial.
Although antibiotics are commonly used to treat symptoms of chronic pelvicpain syndrome, this approach is beneficial in a relatively small subsetof patients, and urologists must consider alternative treatment modalities,including physical therapy. In this exclusive Urology Times interview, JeannettePotts, MD, discusses current research and her own views on the diagnosisand treatment of chronic prostatitis. Dr. Potts is a member of the staffat the Cleveland Clinic Glickman Urological Institute. The interview wasconducted by Philip M. Hanno, MD, of the department of urology, Universityof Pennsylvania, Philadelphia.
Seattle-A new study suggests that a lower PSA threshold for consideringa prostate biopsy may improve the clinical value of the widely used test.In addition, lowering the threshold for biopsy may be particularly importantfor men under the age of 60 years, according to researchers from Brighamand Women's Hospital in Boston and Washington University School of Medicinein St. Louis.
Raritan, NJ-Ortho-McNeil Pharmaceutical has received FDA approval to market levofloxacin (Levaquin) for the treatment of chronic bacterial prostatitis caused by Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.
Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.
Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.
Urologists remain high on the list of in-demand medical specialists in the United States, and their services are even more sought-after than in previous years, according to recently released research. To attract them, hospitals and practices are offering more enticing salaries and other incentives.
FDA OKs treatment for men with testosterone deficiency. Livingston, NJ-The FDA has approved Columbia Laboratories' testosterone buccal system (Striant mucoadhesive) for testosterone replacement therapy. The transbuccal treatment is for men with conditions associated with a deficiency or absence of endogenous testosterone, including hypogonadism.
Advances in available ablative and reconstructive laparoscopic technology have expanded our ability to perform minimally invasive partial nephrectomy. Currently, many patients who are candidates for partial nephrectomy can have their procedures performed laparoscopically.
Chicago-New research on efforts to lower the infection rate among men receiving penile prostheses will likely change how urologists approach this challenging problem, say researchers from three leading Southeastern institutions.
